Toray Industries, Inc. (Head office: Chuo-ku, Tokyo; President: Akihiro Nikkaku; hereinafter referred to as “Toray”) announced today that it signed exclusive distribution agreement covering eight countries in Europe with Fresenius Medical Care AG&Co KGaA (headquarters: Bad Homburg; CEO: Rice Powell; hereinafter referred to as “Fresenius Medical Care”) regarding TORAYMYXIN®*1,*2, a blood purification device for removing endotoxin and PMMA hemofilter*3,*4 for continuous renal replacement therapy, produced by Toray. This agreement awards Fresenius Medical Care the exclusive rights to sell the products in these countries.
Ever since its introduction in 1994, TORAYMYXIN® has been used in clinical practice primarily in Japan to treat severe sepsis and septic shock.
PMMA hemofilter, which is made with polymethylmethacrylate (PMMA) hollow fiber membrane, received approval for manufacturing in 1991 and has been used successfully in many cases, mainly in the emergency and intensive care field to treat acute renal failure and to support organ dysfunction.
With the alliance Toray further expands the market for acute blood purification products in Europe, while Fresenius Medical Care enhances its product lineup with new blood purification products in Europe.
Under the corporate slogan "Innovation by Chemistry," Toray sets out to become "a global top company of advanced materials" by pursuing innovation based on chemistry. For this purpose, it will drive forward creation of new products and technologies by leveraging core technologies of organic synthetic chemistry, polymer chemistry, biotechnology and nanotechnology. The Toray Group also aims to expand the business in the life science field, which it positions as one of "Intensively Developing and Expanding Businesses” that are growth engines under the medium-term management program Project AP-G 2016.
―Countries covered by the sales agreement―
Germany, Denmark, Sweden, Finland, Norway, Poland, Hungary, Czech
